Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1982 1
1983 1
1984 1
1985 4
1986 4
1987 4
1988 3
1989 4
1990 4
1991 4
1992 2
1993 4
1994 4
1995 7
1996 7
1997 7
1998 5
1999 3
2000 1
2001 2
2002 2
2003 4
2004 4
2005 1
2006 2
2007 6
2008 15
2009 15
2010 25
2011 27
2012 25
2013 20
2014 26
2015 24
2016 15
2017 12
2018 12
2019 8
2020 6
2021 8
2022 6
2023 5
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

319 results

Results by year

Filters applied: . Clear all
Page 1
Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration.
Tusch E, Ryom L, Pelchen-Matthews A, Mocroft A, Elbirt D, Oprea C, Günthard HF, Staehelin C, Zangerle R, Suarez I, Vehreschild JJ, Wit F, Menozzi M, d'Arminio Monforte A, Spagnuolo V, Pradier C, Carlander C, Suanzes P, Wasmuth JC, Carr A, Petoumenos K, Borgans F, Bonnet F, De Wit S, El-Sadr W, Neesgaard B, Jaschinski N, Greenberg L, Hosein SR, Gallant J, Vannappagari V, Young L, Sabin C, Lundgren J, Peters L, Reekie J; D:A:D cohort study; RESPOND cohort study. Tusch E, et al. Clin Infect Dis. 2024 Apr 26:ciae228. doi: 10.1093/cid/ciae228. Online ahead of print. Clin Infect Dis. 2024. PMID: 38663013
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.
Moyle G, Assoumou L, de Castro N, Post FA, Curran A, Rusconi S, De Wit S, Stephan C, Raffi F, Johnson M, Masia M, Vera J, Jones B, Grove R, Fletcher C, Duffy A, Morris K, Pozniak A; NEAT ID Foundation and the WISARD study group. Moyle G, et al. Lancet HIV. 2024 Mar;11(3):e156-e166. doi: 10.1016/S2352-3018(23)00292-8. Lancet HIV. 2024. PMID: 38417976 Clinical Trial.
Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT).
Paton NI, Stöhr W, Arenas-Pinto A, Clarke A, Williams I, Johnson M, Orkin C, Chen F, Lee V, Winston A, Gompels M, Fox J, Sanders K, Dunn DT; Protease Inhibitor monotherapy Versus Ongoing Triple therapy (PIVOT) Trial Team. Paton NI, et al. EClinicalMedicine. 2024 Feb 10;69:102457. doi: 10.1016/j.eclinm.2024.102457. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38361989 Free PMC article.
Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human Immunodeficiency Virus.
Chammartin F, Mocroft A, Egle A, Zangerle R, Smith C, Mussini C, Wit F, Vehreschild JJ, d'Arminio Monforte A, Castagna A, Bailly L, Bogner J, de Wit S, Matulionyte R, Law M, Svedhem V, Tallada J, Garges HP, Marongiu A, Borges ÁH, Jaschinski N, Neesgaard B, Ryom L, Bucher HC; RESPOND Study Group. Chammartin F, et al. Clin Infect Dis. 2024 Apr 10;78(4):995-1004. doi: 10.1093/cid/ciad671. Clin Infect Dis. 2024. PMID: 38092042 Free PMC article.
Evolution of CD4 T-Cell Count With Age in a Cohort of Young People Growing Up With Perinatally Acquired Human Immunodeficiency Virus.
Castro H, Sabin C, Collins IJ, Okhai H, Schou Sandgaard K, Prime K, Foster C, Le Prevost M, Crichton S, Klein N, Judd A; Collaborative HIV Paediatric Study; UK Collaborative HIV Cohort Study. Castro H, et al. Clin Infect Dis. 2024 Mar 20;78(3):690-701. doi: 10.1093/cid/ciad626. Clin Infect Dis. 2024. PMID: 37820036 Free PMC article.
Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study.
Álvarez H, Mocroft A, Ryom L, Neesgaard B, Edwards S, Svedhem V, Günthard HF, Zangerle R, Smith C, Castagna A, d'Arminio Monforte A, Wit F, Stecher M, Lehman C, Mussini C, Fontas E, González E, Wasmuth JC, Sönnerborg A, De Wit S, Chkhartishvili N, Stephan C, Petoumenos K, Jaschinski N, Vannappagari V, Gallant J, Young L, Volny Anne A, Greenberg L, Martín-Iguacel R, Poveda E, Llibre JM; RESPOND (International Cohort Consortium of Infectious Diseases) Study Group. Álvarez H, et al. Clin Infect Dis. 2023 Aug 22;77(4):593-605. doi: 10.1093/cid/ciad219. Clin Infect Dis. 2023. PMID: 37052343 Free PMC article.
Hepatitis delta infection among persons living with HIV in Europe.
Béguelin C, Atkinson A, Boyd A, Falconer K, Kirkby N, Suter-Riniker F, Günthard HF, Rockstroh JK, Mocroft A, Rauch A, Peters L, Wandeler G; for EuroSIDA and SHCS. Béguelin C, et al. Liver Int. 2023 Apr;43(4):819-828. doi: 10.1111/liv.15519. Epub 2023 Jan 21. Liver Int. 2023. PMID: 36625770 Free article.
BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022.
Waters L, Winston A, Reeves I, Boffito M, Churchill D, Cromarty B, Dunn D, Fink D, Fidler S, Foster C, Fox J, Gupta R, Hilton A, Khoo S, Leen C, Mackie N, Naous N, Ogbonmwan D, Orkin C, Panton L, Post F, Pozniak A, Sabin C, Walsh J. Waters L, et al. Among authors: leen c. HIV Med. 2022 Dec;23 Suppl 5:3-115. doi: 10.1111/hiv.13446. HIV Med. 2022. PMID: 36504313 No abstract available.
319 results